Skip to main content

New at Switzerland Innovation Park Basel Area: Coretag

| News

New at Switzerland Innovation Park Basel Area: Coretag

09.01.2020

Coretag, a new dynamic biotech company, launches a radioligand platform technology for a range of therapeutic and diagnostic purposes. A radioligand is a radioactive biochemical that is used for diagnostic and therapeutic procedures or for studying the body’s receptor systems. Injected into the relevant tissue or administered into the bloodstream, the radioligand binds to its receptor on tumor cells surfaces. Coretag is determined to rapidly improve care with this platform technology.

Coretag: Elmer Monster, Ermond van Beek, Markwin Maring and Jan van Bodegom (from left to right), img: Roderik van Nispen

Coretag aims to launch an application named NC-Scan for use in patients in 2021. Based on selectively binding to necrotic cells, the NC-Scan will be the world’s first clinical application to determine chemotherapy efficacy within the first week of therapy. Clinical trials with patients with specific solid tumors will start early 2020 at world-renowned leading cancer institutes in Europe and the USA.

This application is a basis for the development of therapeutic agents. Two radioligands therapeutics are in the pipeline, both for the treatment of solid tumor cancer-types. Based on brachy-therapy and hyperthermia, they will have major impact as adjuvant to many existing forms of cancer therapies that are not 100% effective yet.

Coretag’s executive team, originally from the Netherlands, sets its base at the Switzerland Innovations Park Basel Area. They work focused on developing their business. “We are very happy with this location. The atmosphere is dynamic and based on progress. That is how we stand. Great to be here”, says CFO Elmer Monster.

Links

Coretag
Coretag on LinkedIn

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.